Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Evaluation of efficacy and tolerance of radical radiotherapy and radiochemotherapy in treatment of locally advanced, unresectable rectal cancer.
Authors
Małgorzata Kraszkiewicz
Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Gliwice, Poland
Małgorzata Kraszkiewicz , Aleksandra Napieralska , Jerzy Wydmanski , Wojciech Majewski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.133
Abstract #
133
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Correlation between TP53, KRAS, SMAD4 and other mutations profile and neoadjuvant therapy efficacy and prognosis in locally advanced rectal cancer.
First Author: Tomohiro Takeda
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E.
First Author: Takako Yoshii
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.
First Author: Mikako Tamba
Poster
2023 ASCO Annual Meeting
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.
First Author: Michael Michael